Biotest AG / Key word(s): Alliance/Alliance
21.06.2011 14:59
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad-hoc RELEASE
Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)
Dreieich, June 21, 2011 - Abbott and Biotest AG today announced a global
agreement to develop and commercialize BT-061, a novel anti-CD4 antibody
for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is
currently in Phase II clinical trials for RA and psoriasis, with
preclinical studies underway to study its potential use in other
immune-related diseases.
Under the terms of the agreement, Abbott and Biotest will co-promote
BT-061in the five major European markets (Germany, France, United Kingdom,
Italy and Spain) and Abbott will have exclusive global rights to
commercialize BT-061 outside those countries. Biotest will receive an
upfront fee of $85MM. Pending achievement of certain development,
regulatory, commercial and sales-based milestones, Biotest would be
eligible to receive additional milestone payments from Abbott, potentially
amounting to a total of $395MM, and royalties.
Biotest will be responsible for the manufacture of initial clinical supply
of BT-061 and the parties will share responsibility for commercial
production.
Biotest Aktiengesellschaft
The Executive Management Board
Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.de
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasmatic and biotherapeutic drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of
application of immunology and haematology. In its Plasma Protein segment,
Biotest develops and markets immunoglobulins, coagulation factors and
albumins based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. In the Biotherapeutic segment, Biotest
researches into the clinical development of monoclonal antibodies,
including in the indications of rheumatoid arthritis and cancer of plasma
cells. Biotest has more than 1,600 employees worldwide. The preference
shares of Biotest AG are listed in the SDAX on the Frankfurt stock
exchange.
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
21.06.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
LandsteinerstraÃe 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Biotest AG: Agreement with Abbott
| Source: EQS Group AG